ArticleAbdominal radiology (New York)2026
CT-based delta-radiomics nomogram to assess tumor regression grade in locally advanced gastric cancer patients following neoadjuvant chemotherapy.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo develop and validate a delta computed tomography radiomics (delCT-RS) based nomogram for accurate preoperative prediction of tumor regression grade (TRG) in locally advanced gastric cancer (LAGC) patients following neoadjuvant chemotherapy (NAC).
methodsThis retrospective study enrolled 147 LAGC patients. Two delineation strategies were compared: (1) contouring both the primary tumor and the largest lymph node (P + L) as regions of interest (ROIs), and (2) contouring only the primary tumor (P). Subsequently, radiomic features were extracted to construct corresponding radiomic models. This study compared the predictive accuracy of delCT-RS signatures to conventional single-phase radiomic signatures for TRG assessment. Then, delCT-RS signatures and clinical variables were combined into a nomogram. Finally, the prediction performance of nomogram was comprehensively evaluated.
resultsIn assessing tumor response, delCT-RS outperformed single-phase radiomic signatures. Notably, delta computed tomography delCT-RS P + L demonstrated superior accuracy to delCT-RS P (delCT-RS P + L vs. delCT-RS area under the curve (AUC): training cohort: 0.805 vs. 0.727; validation cohort: 0.795 vs. 0.655). The nomogram, combining delCT-RS P + L and clinical factors, achieved optimal performance among all models (training cohort AUC = 0.841; validation cohort AUC = 0.817). (p < 0.05)
conclusionIn this study, we innovatively employed a method that simultaneously delineated the primary tumor and the largest lymph node. This model can accurately predict TRG, effectively identify LAGC patients who can benefit from NAC, and provide scientific support for individualized treatment.
Indexed as
Identifiers
40960514What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.